Context Therapeutics (NASDAQ: CNTX)

Currency in USD

Last close As at 06/02/2023

USD1.00

0.32 (47.06%)

Market capitalisation

USD16m

Context Therapeutics is a clinical-stage biopharma company developing therapeutics for solid tumors, with a primary focus on female cancers. Lead candidate ONA-XR is being evaluated in three Phase II and one Phase Ib/II clinical trial in hormone-driven breast, endometrial and ovarian cancer. The other asset is a bi-specific monoclonal antibody, CLDN6xCD3.

According to the American Cancer Society, there were an estimated 284,200 breast cancer cases, 66,570 endometrial cancer cases and 21,410 ovarian cancer cases in the United States in 2021 (more than 70% of these are hormone-driven). Long-term survival rates remain low (c 30% for HR+/HER2- mBC) despite recent advances, highlighting the high unmet need in the metastatic space.

Doctor with cancer patient

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Jennifer Minai-Azary

    CFO

  • Martin Lehr

    CEO

Balance Sheet

Forecast net cash (US$m)

34.8

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 51.9 (18.2) (57.9)
Relative 39.5 (26.4) (53.7)
52 week high/low US$2.7/US$0.6

Financials

Context Therapeutics has announced that two patients enrolled in the Phase II OATH trial (ONA-XR+anastrozole in advanced endometrial cancer) have achieved partial response (tumor shrinkage) to the treatment. This translates to an overall response rate (ORR) of 22% (two of nine evaluable patients) and strengthens the previously announced positive data from the study (four-month progression free survival (PFS) rate of 77.7%). Management expects to report additional data from the study in Q223 and similar results from a wider cohort should further validate the therapeutic potential of the combination treatment, in our opinion. The beginning of 2023 has been eventful for Context and we expect heightened investor interest given anticipated data readouts from multiple ONA-XR studies (including the SMILE and ELONA trials in breast cancer) later this year.

Y/E Dec Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (fd) (c) P/E (x) P/CF (x)
2020A 0.0 (2.6) (3.2) (928.15) N/A N/A
2021A 0.0 (10.5) (10.6) (373.72) N/A N/A
2022E 0.0 (18.1) (18.1) (113.20) N/A N/A
2023E 0.0 (27.4) (27.4) (171.71) N/A N/A

More from our Healthcare team

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Read latest

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free